Beta‐elemene inhibits breast cancer metastasis through blocking pyruvate kinase M2 dimerization and nuclear translocation

  title={Beta‐elemene inhibits breast cancer metastasis through blocking pyruvate kinase M2 dimerization and nuclear translocation},
  author={Yanhong Pan and Wei Wang and Shuai-Yi Huang and Wenting Ni and Zhonghong Wei and Yuzhu Cao and Su-yun Yu and Qi Jia and Yuanyuan Wu and Chuan Chai and Qian Zheng and Leiming Zhang and Ai-yun Wang and Zhiguang Sun and Shile Huang and Shijun Wang and Wenxing Chen and Yin Lu},
  journal={Journal of Cellular and Molecular Medicine},
  pages={6846 - 6858}
  • Yanhong Pan, W. Wang, +15 authors Yin Lu
  • Published 25 July 2019
  • Medicine, Chemistry
  • Journal of Cellular and Molecular Medicine
Pyruvate kinase M2 (PKM2), playing a central role in regulating aerobic glycolysis, was considered as a promising target for cancer therapy. However, its role in cancer metastasis is rarely known. Here, we found a tight relationship between PKM2 and breast cancer metastasis, demonstrated by the findings that beta‐elemene (β‐elemene), an approved drug for complementary cancer therapy, exerted distinct anti‐metastatic activity dependent on PKM2. The results indicated that β‐elemene inhibited… 
β-elemene inhibits non-small cell lung cancer cell migration and invasion by inactivating the FAK-Src pathway
The results suggest that β-elemene potentially inhibits NSCLC through FAK-Src signaling, which involves focal adhesion kinase (FAK)-mediated cell migration and invasion via complex formation with Src.
Targeting Pyruvate Kinase M2 Phosphorylation Reverses Aggressive Cancer Phenotypes
In a TNBC mouse xenograft model, treatment with either TEPP-46 or the potent CDK inhibitor Dinaciclib reduced tumor growth and diminished PKM2pS37, and data support an approach to identify PKM 2pS 37-positive TNBC and target thePKM2 regulatory axis as a potential treatment.
β-elemene promotes the senescence of glioma cells through regulating YAP-CDK6 signaling.
Results reveal a previously unknown role of β-elemene in glioma cell senescence in vitro and in vivo that is associated with YAP-CDK6 signaling pathway, which will enhance the understanding of gliomas, and provide novel strategies for the treatment ofgliomas.
β-elemene suppresses Warburg effect in NCI-H1650 non-small-cell lung cancer cells by regulating the miR-301a-3p/AMPKα axis
It is indicated that β-elemene attenuates the Warburg effect in NSCLC cells, possibly by mediating the miR-301a-3p/AMPKα axis.
A short review on cross-link between pyruvate kinase (PKM2) and Glioblastoma Multiforme.
Pyruvate kinase (PK) catalyzes the last irreversible reaction of glycolysis pathway, generating pyruvate and ATP, from Phosphoenol Pyruvate (PEP) and ADP precursors. In mammals, four different
Resibufogenin suppresses tumor growth and Warburg effect through regulating miR-143-3p/HK2 axis in breast cancer
The findings suggested that RES exerted anti-tumorigenesis and anti-glycolysis activities in breast cancer through upregulating the inhibitory effect of miR-143-3p on HK2 expression, which provided a new potential strategy for breast cancer clinical treatment.
The mechanism of m6A methyltransferase METTL3-mediated autophagy in reversing gefitinib resistance in NSCLC cells by β-elemene
The mechanism of METTL3-mediated autophagy in reversing gefitinib resistance of NSCLC cells by β-elemene is unveiled, which shed light on providing potential molecular-therapy target and clinical-treatment method in NSclC patients with gefitsinib resistant cells.
Beta-Elemene Suppresses Metastasis of Human Esophageal Cancer Cell by Downregulating Heat Shock Protein 70/Mothers against Decapentaplegic Homolog 2 Pathway
  • W. C. Gao, W. J. Chen
  • Indian Journal of Pharmaceutical Sciences
  • 2021
In this study, we tried to illuminate the role and underlying mechanism of beta-elemene in esophageal squamous cell carcinoma especially the metastasis. 3-(4, 5-dimethylthiazolyl-2)-2,
Combinative treatment of β-elemene and cetuximab is sensitive to KRAS mutant colorectal cancer cells by inducing ferroptosis and inhibiting epithelial-mesenchymal transformation
The data for the first time suggest that the natural product β-elemene is a new ferroptosis inducer and combinative treatment of β- elemene and cetuximab is sensitive to KRAS mutant CRC cells by inducing ferroPTosis and inhibiting EMT, which will hopefully provide a prospective strategy for CRC patients with RAS mutations.
PTEN: What we know of the function and regulation of this onco-suppressor factor in bladder cancer?
The role of PTEN in bladder cancer cells and how upstream modulators affect PTEN is explored and how anti-tumor drugs such as kaempferol, β-elemene and sorafenib upregulate the expression ofPTEN to exert their inhibitory effects on bladder cancer Cells.


Pyruvate kinase M2 deregulation enhances the metastatic potential of tongue squamous cell carcinoma
According to the microarray analysis and Western blots, PKM2 expression was up-regulated in TSCC cells with enhanced metastatic potential and may serve as a biomarker of metastasis potential or as a therapeutic target in patients with TSCC.
Nuclear PKM2 regulates β-catenin transactivation upon EGFR activation
Findings reveal that EGF induces β-catenin transactivation via a mechanism distinct from that induced by Wnt/Wingless and highlight the essential non-metabolic functions of PKM2 in EGFR-promoted β- catenintransactivation, cell proliferation and tumorigenesis.
PKM2 promotes cell migration and inhibits autophagy by mediating PI3K/AKT activation and contributes to the malignant development of gastric cancer
In vitro cell biological behavior, in vivo tumorigenicity studies, and primary GC samples revealed an oncogenic role for PKM2 in GC, and for those GC patients who received radical resection,PKM2 might serve as a novel prognostic biomarker and target which would allow for a new treatment strategy for GC in the clinical settings.
The Role of E3 Ubiquitin Ligase Cbl Proteins in β-Elemene Reversing Multi-Drug Resistance of Human Gastric Adenocarcinoma Cells
β-elemene treatment markedly increased the intracellular accumulation of doxorubicin (DOX) and rhodamine 123 in both K562/DNR and SGC7901/ADR cells and significantly inhibited the expression of P-gp, suggesting it may target P- gp-overexpressing leukemia and gastric cancer cells to enhance the efficacy of DOX treatment.
p53 and glucose metabolism: an orchestra to be directed in cancer therapy.
This review emphasizes the p53 activation as a promising therapeutic strategy to reprogram tumor glucose metabolism, conducting to cell death, and potential synergisms between p53-activating agents and metabolic inhibitors are discussed, fostering the improvement of cancer therapy.
ERK1/2-dependent phosphorylation and nuclear translocation of PKM2 promotes the Warburg effect.
It is demonstrated that EGFR-activated ERK2 binds directly to PKM2 Ile 429/Leu 431 through the ERK1/2 docking groove and phosphorylatesPKM2 at Ser 37, but does not phosphorylate PKM1, highlighting the importance of nuclear functions of PKM 2 in the Warburg effect and tumorigenesis.
PKM2 and cancer: The function of PKM2 beyond glycolysis
The improved understanding of PKM2 may provide a noval approach for cancer treatment, and its role as a coactivator and protein kinase, which contributes to tumorigenesis is reviewed.
The reversal of antineoplastic drug resistance in cancer cells by β-elemene
The mechanisms by which β-elemene, a compound extracted from Rhizoma zedoariae that has clinical antitumor efficacy, overcomes drug resistance in cancer are discussed.
Mitogenic and oncogenic stimulation of K433 acetylation promotes PKM2 protein kinase activity and nuclear localization.
K433 acetylation links cell proliferation and transformation to the switch of PKM2 from a cytoplasmic metabolite kinase to a nuclear protein kinase.
Anti-tumor effect of beta-elemene in glioblastoma cells depends on p38 MAPK activation.
Findings indicate that activation of p38 MAPK is critical for the anti-proliferation effect of beta-elemene and that p38MAPK might be a putative pharmacological target for glioblastoma therapy.